SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Transfusion Medicine and Hemostasis
Clinical and Laboratory Aspects
- 4th Edition - November 16, 2024
- Editors: Beth H. Shaz, Christopher D. Hillyer, Joseph (Yossi) Schwartz, Morayma Reyes Gil
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 6 0 1 4 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 6 0 1 5 - 1
Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Fourth Edition continues to be the only "pocket-size" quick reference for pathology and transfusion medicine… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTransfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Fourth Edition continues to be the only "pocket-size" quick reference for pathology and transfusion medicine for residents and fellows. It is helpful to all physicians and allied health professionals who order and administer blood components, cellular therapies, specialized factors for hemostatic abnormalities, coagulation testing, and those who consult and care for these often very ill patients. This book is ideal for pathology, medicine, surgery, and anesthesia residents, transfusion, hematology, and anesthesia fellows, and certified and specialized practitioners, as well as medical technologist in transfusion, cellular therapy, hematology, and coagulation. This new edition covers the many new developments that have occurred since the previous edition to include new blood products, new indications, or clinical conditions in which blood products are used. Similarly, new hemostasis testing is introduced as well as new clinical scenarios due the COVID-19 pandemic that area relevant to hemostasis and transfusion medicine. This includes COVID coagulopathy, Vaccine Induced Thrombotic Immune Thrombocytopenia, Pediatric reference range in coagulation testing, Platelet rich plasma and MNC products – CAR-T cells.
- Includes COVID-19 coagulopathy and Vaccine Induced Thrombotic Immune N94 Thrombocytopenia
- Provides all information regarding the clinical and laboratory aspects of Transfusion Medicine and Hemostasis in one place
- Presents user-friendly, up-to-date information in a book that can be carried around either to the lab or bedside
Transfusion Medicine practitioners, Transfusion Medicine fellows, Pathology residents, Hematology practitioners, Hematology fellows, Laboratory personnel
1. Blood banking and transfusion medicine – the field, the discipline and the industry
2. Quality principles in Transfusion medicine
3. Regulatory issues in transfusion medicine
4. Role of the physician in the blood center
5. Blood donor, donation process and technical aspects of blood collection
6. Apheresis blood component collections
7. Recipient-specific blood donations
8. Adverse donor reactions (iron)
9. Component preparation and manufacturing
10. Serologic testing of donor products
11. Overview of infectious disease testing
12. HIV screening
13. Hepatitis B screening
14. Hepatitis C screening
15. WNV screening
16. Zika screening
17. Babesia screening
18. Syphilis, HTLV and Chagas screening
19. Bacterial mitigation of platelets
20. Role of the transfusion service physician
21. Pretransfusion testing
22. Antibody identification
23. Direct antiglobulin test
24. Molecular DNA based blood group typing
25. ABO and H blood group systems
26. RH and RhAg blood group system
27. KELL and KIDD blood group systems
28. MNS AND DUFFY blood group systems
29. LEWIS, I P1Pk and Glob blood group systems
30. Other blood group systems, collections, and antigens
31. Human platelet and neutrophil antigens
32. HLA Antigens
33. Red blood cells products
34. Plasma products
35. Platelet products (to include PAS if not previously mentioned; was mentioned In the 2nd edition)
36. Cryoprecipitate and fibrinogen concentrates
37. Granulocyte products
38. Albumin and related products
39. Human immunoglobuin preparations
40. Rh immune globulin
41. Coagulation Factor products
42. Platelet rich plasma
43. Convalescent plasma, including COVID convalescent plasma
42. Nonfactor therapies for bleeding disorders
44. Blood Pharming and alternative blood production methods
45. Irradiation of blood products
44. Leukoreduction of blood products
46. CMV-safe blood products
47. Frozen blood products
48. Washed blood products
49. Volume reduced blood products
50. Pathogen reduction technologies
51. Intrauterine, Neonatal and pediatric transfusion medicine
52. Perinatal transfusion medicine
53. AutoImmune hemolytic anemias
54. Transfusion management in patients with hemoglobinopathies
55. Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplantation
56. Transfusion of Patients Undergoing Solid Organ Transplantation
57. Transfusion support and hemostatic monitoring in patients connected to extracorporeal devices
58. Transfusion of patients receiving antithrombotic therapy
59. Blood transfusion in economically restricted and developing countries
60. Management of Patients Who Refuse Blood Transfusion
61. Platelet transfusion refractory patients
62. Massive transfusion
63. Patient blood management
64. Overview of adverse events and outcomes following transfusion
65. Febrile non-hemolytic transfusion reactions
66. Allergic transfusion reactions
67. Acute hemolytic transfusion reactions
68. Delayed hemolytic transfusion reactions
69. Transfusion-Associated Circulatory Overload
70. Transfusion-Related Acute Lung Injury
71. Septic transfusion reactions
72. Metabolic, hypotensive and other acute reactions and complications
73. Post transfusion purpura
74. Transfusion associated graft versus host disease
75. Transfusion related immunomodulation
76. Iron Overload
77. Transfusion transmitted diseases
78. Overview to therapeutic apheresis
79. Therapeutic plasma exchange
80. Therapeutic erythrocytapheresis
81. Therapeutic thrombocytapheresis
82. Therapeutic leukocytapheresis and adsorptive cytapheresis
83. Extracorporeal photopheresis
84. LDL apheresis
85. Immunoabsorption
86. COVID-19 & Apheresis
87. Therapeutic phlebotomy
88. Overview of cellular therapy
89. HPC products derived from bone marrow and peripheral blood
90. Cord blood banking (expansion)
91. Regenerative medicine (iPS)
92. Immunotherpy (T cells): CAR-T, TILs, gene therapy and more
93. Adverse events associated with HPC product infusion
94. Quality and regulatory issues in cellular therapy
95. Tissue banking in the hospital setting
96. Overview of the coagulation system
97. Approach to the patient with a bleeding disorder
98. Congenital thrombocytopenia
99. fetal and Neonatal alloimmune thrombocytopenia
100. Acquired neonatal thrombocytopenia
101. Bernard Soulier syndrome and other GPIb-IX-V related receptor defects
102. Glanzmann's thrombocytopenia
103. Other platelet glycoprotein disorders
104. Platelet storage-granule defects
105. Failure to release and aspirin-like defects
106. Other Platelet abnormalities
107. Acquired platelet disorders
108. Acute (childhood) ITP
109. Chronic ITP
110. Drug induced thrombocytopenia
111. Heparin induced thrombocytopenia
112. Vaccine Induced Thrombotic Immune Thrombocytopenia
113. Autoimmune lymphoproliferative syndrome
114. Hemolytic uremic syndrome
115. Thrombotic thrombocytopenic purpura
116. Antiphospholipid syndrome
117. Von Willebrand Disease
118. Hemophilia A
119. Hemophilia B
120. Congenital disorders of fibrinogen
121. Factor XIII, D α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 deficiencies
122. Factor XI deficiency
123. Factor VII deficiency
124. Factor II, factor V, and factor X deficiencies
125. Bleeding disorders in pregnancy
126. Vascular bleeding disorders
127. Hemostasis in Liver Disease
128. Bleeding risks with Vitamin K deficiency
129. Bleeding risks with cardiac disease
130. Bleeding risks with renal disease
131. Bleeding risks with cancer
132. Disseminated intravascular coagulopathy
133. coagulopathy in sickle cell disease and other hemoglobiniopathies
134. COVID coagulopathy
135. Thrombosis in COVID Coagulopathy---Anticoagulation guidelines
136. Bleeding in COVID coagulopathy
137. Acquired coagulation factor inhibitors
138. Overview of purposes of hemostasis testing and common sources of error
139. Pediatric reference ranges in coagulation testing
140. Prothrombin Time
141. Activated Partial Thrombolplastin Time
142. Mixing studies
143. Coagulation Factor Testing
144. Testing of Nonfactor therapies: emicizumab
145: Testing of Nonfactor therapies: inhibitors of anticoagulant pathways (fitusiran and concizumab)
146. Specific Factor Inhibitor Testing
147. Thrombin time and Fibrinogen Evaluation
148. laboratory diagnosis of inherited von Willebrand Disease
149. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome
150. Laboratory Assessment of Treatment of von Willebrand’s Disease
151. Measurement of platelet count, mean platelet volume, and reticulated platelets
152. Platelet Function Analyzer
153. thromboelastography/thromboelastometry
154. Platelet Aggregation Studies
155. Laboratory Diagnosis of Platelet Functional Defects
156. Confirmatory testing for diagnosis of platelet disorders
157. Platelets in COVID coagulopathy
158. Anti-platelet Therapy Monitoring
159. Laboratory evaluation of factor XIII deficiency
160. Fibrinolytic testing
161. Age-adjusted D-Dimer cut offs to rule out PE/ VTE 162. Laboratory techniques in fibrinolysis testing
163. Laboratory evaluation of long-term thrombophilic disorders
164. Thrombophilia testing in children
165. Antithrombin Testing
166. Protein C deficiency evaluation
167. Protein S deficiency evaluation
168. testing for Activated Protein C Resistance
169. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in inherited thrombophilia
170. Chronic elevated levels of Factor VIII and other coagulation factors
171. Laboratory Monitoring for Heparins, fondaparinux, direct thrombin inhibitors, and oral anti-Xa medications
172: DOAC interferences in coagulation testing
173. Laboratory testing in patients receiving DOAC antidotes
174. Laboratory support for warfarin monitoring
175. Molecular testing in Coagulation
176. Acquired prothrombotic conditions
177: Ventricular assist device: anticoagulation monitoring
178. Laboratory Evaluation of Heparin-Induced Thrombocytopenia
179. Laboratory Evaluation of Thrombotic Thromcytopenic Purpura
180. D-Dimer testing in COVID coagulopathy
181. Other coagulation tests in COVID coagulopathy
182. Laboratory diagnosis of lupus anticoagulant and anti-phopholipid antibodies
183. Lupus anticoagulant testing in COVID-19
184. Circulating microparticles
185. Thrombin Generation Assays
186. Laboratory testing of contact factors
187. Contact factors and complements
188. Monitoring of new anticoagulants---inhibitors of contact factors
189. Reference ranges in transgender
2. Quality principles in Transfusion medicine
3. Regulatory issues in transfusion medicine
4. Role of the physician in the blood center
5. Blood donor, donation process and technical aspects of blood collection
6. Apheresis blood component collections
7. Recipient-specific blood donations
8. Adverse donor reactions (iron)
9. Component preparation and manufacturing
10. Serologic testing of donor products
11. Overview of infectious disease testing
12. HIV screening
13. Hepatitis B screening
14. Hepatitis C screening
15. WNV screening
16. Zika screening
17. Babesia screening
18. Syphilis, HTLV and Chagas screening
19. Bacterial mitigation of platelets
20. Role of the transfusion service physician
21. Pretransfusion testing
22. Antibody identification
23. Direct antiglobulin test
24. Molecular DNA based blood group typing
25. ABO and H blood group systems
26. RH and RhAg blood group system
27. KELL and KIDD blood group systems
28. MNS AND DUFFY blood group systems
29. LEWIS, I P1Pk and Glob blood group systems
30. Other blood group systems, collections, and antigens
31. Human platelet and neutrophil antigens
32. HLA Antigens
33. Red blood cells products
34. Plasma products
35. Platelet products (to include PAS if not previously mentioned; was mentioned In the 2nd edition)
36. Cryoprecipitate and fibrinogen concentrates
37. Granulocyte products
38. Albumin and related products
39. Human immunoglobuin preparations
40. Rh immune globulin
41. Coagulation Factor products
42. Platelet rich plasma
43. Convalescent plasma, including COVID convalescent plasma
42. Nonfactor therapies for bleeding disorders
44. Blood Pharming and alternative blood production methods
45. Irradiation of blood products
44. Leukoreduction of blood products
46. CMV-safe blood products
47. Frozen blood products
48. Washed blood products
49. Volume reduced blood products
50. Pathogen reduction technologies
51. Intrauterine, Neonatal and pediatric transfusion medicine
52. Perinatal transfusion medicine
53. AutoImmune hemolytic anemias
54. Transfusion management in patients with hemoglobinopathies
55. Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplantation
56. Transfusion of Patients Undergoing Solid Organ Transplantation
57. Transfusion support and hemostatic monitoring in patients connected to extracorporeal devices
58. Transfusion of patients receiving antithrombotic therapy
59. Blood transfusion in economically restricted and developing countries
60. Management of Patients Who Refuse Blood Transfusion
61. Platelet transfusion refractory patients
62. Massive transfusion
63. Patient blood management
64. Overview of adverse events and outcomes following transfusion
65. Febrile non-hemolytic transfusion reactions
66. Allergic transfusion reactions
67. Acute hemolytic transfusion reactions
68. Delayed hemolytic transfusion reactions
69. Transfusion-Associated Circulatory Overload
70. Transfusion-Related Acute Lung Injury
71. Septic transfusion reactions
72. Metabolic, hypotensive and other acute reactions and complications
73. Post transfusion purpura
74. Transfusion associated graft versus host disease
75. Transfusion related immunomodulation
76. Iron Overload
77. Transfusion transmitted diseases
78. Overview to therapeutic apheresis
79. Therapeutic plasma exchange
80. Therapeutic erythrocytapheresis
81. Therapeutic thrombocytapheresis
82. Therapeutic leukocytapheresis and adsorptive cytapheresis
83. Extracorporeal photopheresis
84. LDL apheresis
85. Immunoabsorption
86. COVID-19 & Apheresis
87. Therapeutic phlebotomy
88. Overview of cellular therapy
89. HPC products derived from bone marrow and peripheral blood
90. Cord blood banking (expansion)
91. Regenerative medicine (iPS)
92. Immunotherpy (T cells): CAR-T, TILs, gene therapy and more
93. Adverse events associated with HPC product infusion
94. Quality and regulatory issues in cellular therapy
95. Tissue banking in the hospital setting
96. Overview of the coagulation system
97. Approach to the patient with a bleeding disorder
98. Congenital thrombocytopenia
99. fetal and Neonatal alloimmune thrombocytopenia
100. Acquired neonatal thrombocytopenia
101. Bernard Soulier syndrome and other GPIb-IX-V related receptor defects
102. Glanzmann's thrombocytopenia
103. Other platelet glycoprotein disorders
104. Platelet storage-granule defects
105. Failure to release and aspirin-like defects
106. Other Platelet abnormalities
107. Acquired platelet disorders
108. Acute (childhood) ITP
109. Chronic ITP
110. Drug induced thrombocytopenia
111. Heparin induced thrombocytopenia
112. Vaccine Induced Thrombotic Immune Thrombocytopenia
113. Autoimmune lymphoproliferative syndrome
114. Hemolytic uremic syndrome
115. Thrombotic thrombocytopenic purpura
116. Antiphospholipid syndrome
117. Von Willebrand Disease
118. Hemophilia A
119. Hemophilia B
120. Congenital disorders of fibrinogen
121. Factor XIII, D α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 deficiencies
122. Factor XI deficiency
123. Factor VII deficiency
124. Factor II, factor V, and factor X deficiencies
125. Bleeding disorders in pregnancy
126. Vascular bleeding disorders
127. Hemostasis in Liver Disease
128. Bleeding risks with Vitamin K deficiency
129. Bleeding risks with cardiac disease
130. Bleeding risks with renal disease
131. Bleeding risks with cancer
132. Disseminated intravascular coagulopathy
133. coagulopathy in sickle cell disease and other hemoglobiniopathies
134. COVID coagulopathy
135. Thrombosis in COVID Coagulopathy---Anticoagulation guidelines
136. Bleeding in COVID coagulopathy
137. Acquired coagulation factor inhibitors
138. Overview of purposes of hemostasis testing and common sources of error
139. Pediatric reference ranges in coagulation testing
140. Prothrombin Time
141. Activated Partial Thrombolplastin Time
142. Mixing studies
143. Coagulation Factor Testing
144. Testing of Nonfactor therapies: emicizumab
145: Testing of Nonfactor therapies: inhibitors of anticoagulant pathways (fitusiran and concizumab)
146. Specific Factor Inhibitor Testing
147. Thrombin time and Fibrinogen Evaluation
148. laboratory diagnosis of inherited von Willebrand Disease
149. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome
150. Laboratory Assessment of Treatment of von Willebrand’s Disease
151. Measurement of platelet count, mean platelet volume, and reticulated platelets
152. Platelet Function Analyzer
153. thromboelastography/thromboelastometry
154. Platelet Aggregation Studies
155. Laboratory Diagnosis of Platelet Functional Defects
156. Confirmatory testing for diagnosis of platelet disorders
157. Platelets in COVID coagulopathy
158. Anti-platelet Therapy Monitoring
159. Laboratory evaluation of factor XIII deficiency
160. Fibrinolytic testing
161. Age-adjusted D-Dimer cut offs to rule out PE/ VTE 162. Laboratory techniques in fibrinolysis testing
163. Laboratory evaluation of long-term thrombophilic disorders
164. Thrombophilia testing in children
165. Antithrombin Testing
166. Protein C deficiency evaluation
167. Protein S deficiency evaluation
168. testing for Activated Protein C Resistance
169. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in inherited thrombophilia
170. Chronic elevated levels of Factor VIII and other coagulation factors
171. Laboratory Monitoring for Heparins, fondaparinux, direct thrombin inhibitors, and oral anti-Xa medications
172: DOAC interferences in coagulation testing
173. Laboratory testing in patients receiving DOAC antidotes
174. Laboratory support for warfarin monitoring
175. Molecular testing in Coagulation
176. Acquired prothrombotic conditions
177: Ventricular assist device: anticoagulation monitoring
178. Laboratory Evaluation of Heparin-Induced Thrombocytopenia
179. Laboratory Evaluation of Thrombotic Thromcytopenic Purpura
180. D-Dimer testing in COVID coagulopathy
181. Other coagulation tests in COVID coagulopathy
182. Laboratory diagnosis of lupus anticoagulant and anti-phopholipid antibodies
183. Lupus anticoagulant testing in COVID-19
184. Circulating microparticles
185. Thrombin Generation Assays
186. Laboratory testing of contact factors
187. Contact factors and complements
188. Monitoring of new anticoagulants---inhibitors of contact factors
189. Reference ranges in transgender
- No. of pages: 1000
- Language: English
- Edition: 4
- Published: November 16, 2024
- Imprint: Elsevier Science
- Paperback ISBN: 9780323960144
- eBook ISBN: 9780323960151
BS
Beth H. Shaz
Beth H. Shaz, MD, is Chief Medical and Scientific Officer, Executive Vice President at New York Blood Center, and Adjunct Assistant Professor, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University. Beth is responsible for all medical and scientific activities throughout the NYBC network, which includes Rhode Island Blood Center, Innovative Blood Resources (Memorial Blood Center and Nebraska Blood Center), Community Blood Center of Greater Kansas City, and Blood Bank of Delmarva. Medical activities comprise of hemophilia services, clinical apheresis services, perioperative autologous transfusion services, cellular therapy, medical education, medical consultation, transfusion services, bone marrow donor recruitment, and donor management. Scientific activities include basic science at the Lindsey F. Kimball Research Institute and Comprehensive Cell Solutions (CCS), which contains translational and clinical research. NYBC’s scientific and medical activities focus on transfusion medicine, cell therapy, regenerative medicine, infectious disease, hematology, and personalized medicine. Beth is an editor of ten books in transfusion medicine, author of over 130 articles pertaining to transfusion medicine. She is an associate editor of TRANSFUSION and on the editorial board of BLOOD. Previously, she was an Associate Professor at Emory University School of Medicine and director of the transfusion service at Grady Memorial Hospital. Also, she was an instructor at Harvard Medical School and associate director of the transfusion service at Beth Israel Deaconess Medical Center in Boston. Beth received her MD with research distinction from the University of Michigan and BS in chemical engineering with distinction from Cornell University. She completed a general surgery internship at Georgetown University, an anatomic & clinical pathology residency at Beth Israel Deaconess Medical Center, and a transfusion medicine fellowship at Harvard Medical School.
Affiliations and expertise
Chief Medical and Scientific Officer and Executive Vice President, New York Blood Center and Adjunct Assistant Professor, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USACH
Christopher D. Hillyer
Christopher D. Hillyer, MD, is President and CEO of New York Blood Center and Professor, Department of Medicine, Weill Cornell Medical College, New York, NY. Previously, he was the tenured, endowed Distinguished Service Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine and served as director of the Emory Center for Transfusion and Cellular Therapies with responsibility for all aspects of clinical and academic transfusion medicine at Emory’s seven principle hospitals. Dr. Hillyer is an editor of twelve textbooks in transfusion medicine, author of over 160 articles pertaining to transfusion, human immunodeficiency virus, and herpes viruses, most notably cytomegalovirus. Nationally recognized as an expert in hematology and blood transfusion, Dr. Hillyer is also a past-president, board of directors of AABB and a former trustee of the National Blood Foundation. Dr. Hillyer has been awarded many million dollars in research funding from the National Institutes of Health, the Centers for Disease Control and Prevention and other agencies. He was an associate editor of Transfusion and serves on several other editorial boards. Dr. Hillyer was formally recognized for his work in Africa as part of the AABB/Emory cooperative agreement from the President’s Emergency Plan For AIDS Relief (PEPFAR), and is a recipient of two Tiffany Awards from the American Red Cross where he also served as a medical director and a member of their national Medical Advisory Board. He also received the 2014 Emily Cooley Award from AABB for his “significant commitment and contributions to the field of transfusion medicine through extensive teaching, mentoring and professional leadership, and the countless clinical, scientific and innovative resource materials he has created to educate others”. He is a co-founder of Transfusion & Transplantation Technologies, Inc (3Ti) and holds over 20 patents or patents pending. Dr. Hillyer is board certified in transfusion medicine, hematology, medical oncology and internal medicine. He received his BS from Trinity College, and his MD from the University of Rochester School of Medicine, with postgraduate training and fellowships in hematology-oncology, transfusion medicine and bone marrow transplantation at Tufts-New England Medical Center.
Affiliations and expertise
President and Chief Executive Officer, New York Blood Center and Professor, Department of Medicine, Weill Cornell Medical College, New York, NY, USAJS
Joseph (Yossi) Schwartz
Joseph (Yossi) Schwartz, MD, MPH received his MD from the Technion – Israel Institute of Technology and his MPH from Columbia University Mailman School of Public Health. He completed Internal Medicine & Hematology Fellowship in Israel and then completed Transfusion Medicine/Blood Banking fellowship at the New York Blood Center.
He was as previously a Professor of Pathology & Cell Biology at the Columbia University Medical Center and served as the Director of the Transfusion Medicine & Cellular Therapy Service. He oversaw the Blood Bank, The Cell Therapy facility and the Apheresis unit.
Affiliations and expertise
Professor of Pathology, Molecular and Cell–based Medicine, Icahn School of Medicine, Mount Sinai, NY, USAMG
Morayma Reyes Gil
Morayma Reyes Gil, MD, PhD, is an associate professor in the Department of Pathology at Montefiore Medical Center (MMC) and Albert Einstein College of Medicine. As the director of hematology and special coagulation laboratories, Dr. Reyes Gil oversees all hematology and coagulation laboratories at all MMC hospitals, collaborates in clinical research and clinical trial studies and continues translational research in vascular biology. She started her career in academic pathology at the University of Washington as an assistant professor in the Department of Pathology and laboratory Medicine. Dr. Reyes Gil has been a recipient of several awards and research grants from private research foundations and from the National Institutes of Health. Dr. Reyes Gil is board certified in clinical pathology and has authored over 50 peer-reviewed articles in the field of vascular biology. Dr. Gil is a graduate of the University of Puerto Rico. She received her MD and PhD from the University of Minnesota. She then completed a residency in clinical pathology and specialized in coagulation and benign hematology at the University of Washington.
Affiliations and expertise
Director of Hematology and Coagulation Laboratories, Montefiore Medical Center and Associate Professor, Department of Pathology and Laboratory Medicine, Albert Einstein College of Medicine, New York, NY, USARead Transfusion Medicine and Hemostasis on ScienceDirect